Travel restrictions could stall deal flow, fundraising and more as COVID-19 outbreak progresses

The inability to hold face-to-face meetings as the coronavirus crisis deepens globally will have broad impacts across the biopharma industry on everything from dealmaking and fundraising to regulatory progress.

For Apollomics Inc., a cancer company split between sites in Hangzhou and the Bay Area, most of the disruptions it’s encountered have been felt on its China side, but that could all change as the virus takes root in new regions. ...